Researchers in Tromsø have discovered a new bacteriocin in a common skin bacterium, named Romsacin, which shows potential in combating antibiotic-resistant bacteria. This discovery could lead to new treatments for infections currently without effective remedies. The process of developing Romsacin into a usable drug involves extensive research, testing, and compliance with bureaucratic processes, underscoring the long and uncertain journey of medical advancements.
Infections with antibiotic-resistant bacteria are an escalating global concern. The solution may partly involve emulating the bacteria’s own weaponry. A new bacteriocin, discovered in a common skin bacterium by researchers in Tromsø, shows promise. This bacteriocin effectively inhibits the growth of antibiotic-resistant bacteria, which are frequently implicated in diseases and pose treatment challenges.
One million deaths each year
The fact that we have medicines against bacterial infections is something many people take for granted. But increasing resistance among bacteria means that more and more antibiotics do not work. When the bacteria become resistant to the antibiotics we have available, we are left without a treatment option for very common diseases. Over one million people die each year as a result of antibiotic resistance.
The first step in developing new antibiotics is to look for substances that inhibit bacterial growth.
Sami name for an exciting discovery
The research group for child and youth health at UiT The Arctic University of Norway has studied substances that the bacteria themselves produce to inhibit the growth of competitors. These substances are called bacteriocins. Through the work, they have discovered a new bacteriocin, in a very common skin bacterium. Bacteriocin inhibits the growth of antibiotic-resistant bacteria that can be difficult to treat with common antibiotics.
Runa Wolden in the lab at UiT. Credit: Jørn Berger-Nyvoll/UiT
The researchers have called the new bacteriocin Romsacin, after the Sami name for Tromsø, Romsa. The hope is that Romsacin can be developed into a new medicine for infections for which there is currently no effective treatment.
Long way to go
At the same time, researcher Runa Wolden at the Department of Clinical Medicine at UiT emphasizes that there is a long way to go before it is known whether Romsacin will be developed and taken into use as a new medicine. Because that’s how it is with basic research; you cannot say in advance when someone will make use of the results you produce.
“This discovery is the result of something we have been researching for several years. Developing Romsacin – or other promising substances – into new antibiotics is very expensive and can take 10-20 years,” says Wolden, who is part of the research group for child and youth health.
Effective against bacterial types
Before new antibiotics can be used as medicines, one needs to make sure that they are safe to use. Currently, researchers do not know how the bacteriocin works in humans. A further process will involve comprehensive testing, bureaucracy, and marketing.
“This naturally means that there is a long way to go before we can say anything for sure. What we already know, however, is that this is a new bacteriocin, and that it works against some types of bacteria that are resistant to antibiotics. It’s exciting,” says Wolden.
The new bacteriocin is produced by a bacterium called Staphylococcus haemolyticus. The bacteriocin is not produced by all S. haemolyticus, but by one of the 174 isolates that the researchers have available in the freezer.
“We couldn’t know that before we started the project, and that’s one of the things that makes research fun,” says Wolden.
She says that ten years ago the researchers collected bacterial samples from healthy people when they wanted to compare S. haemolyticus in healthy people with those found in patients in hospital.
“Subsequently, we have done many experiments with these bacteria, and this is the result from one of our projects,” says Runa Wolden.
Reference: “The novel bacteriocin romsacin from Staphylococcus haemolyticus inhibits Gram-positive WHO priority pathogens” by Runa Wolden, Kirill V. Ovchinnikov, Hermoine J. Venter, Thomas F. Oftedal, Dzung B. Diep and Jorunn Pauline Cavanagh, 31 October 2023, Microbiology Spectrum.
DOI: 10.1128/spectrum.00869-23
Source: SciTechDaily
